Company profile: Imbria
1.1 - Company Overview
Company description
- Provider of clinical-stage cardiometabolic therapies centered on ninerafaxstat, an investigational cardiac mitotrope designed to enhance cellular energy metabolism by increasing energy per molecule of oxygen consumed. Conducts Phase 2 trials: IMPROVE-HCM (non-obstructive HCM), IMPROVE-ISCHEMIA (stable angina/chronic coronary syndrome), and IMPROVE-DiCE (type 2 diabetes with HFpEF).
Products and services
- Ninerafaxstat: Imbria engineers an investigational-grade cardiac mitotrope that enhances cellular energy metabolism by increasing energy produced per oxygen molecule, in Phase 2 for nHCM, stable angina, and HFpEF
- IMPROVE-DiCE Phase 2 Clinical Trial: A two-part, MR spectroscopy-based study evaluating safety, tolerability, and pharmacodynamic effects of ninerafaxstat in type 2 diabetes with HFpEF, measuring metabolic and energetic responses
- IMPROVE-HCM Phase 2 Clinical Trial: Investigates ninerafaxstat’s safety and efficacy in non-obstructive hypertrophic cardiomyopathy, emphasizing exercise limitation and patient-reported symptoms as primary functional assessments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Imbria
ViroPharma
HQ: United States
Website
- Description: Provider of biopharmaceutical products addressing serious diseases, focused on therapies used by physician specialists or in hospital settings; develops and commercializes treatments, with two marketed products and three development programs, including Vancocin HCl capsules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ViroPharma company profile →
Faraday Pharma
HQ: United States
Website
- Description: Provider of early-stage therapeutics targeting ischemia-reperfusion injury, led by FDY-5301, a sodium iodide formulation in Phase 3 to reduce injury after myocardial infarction and potentially decrease heart failure and cardiovascular death. Advancing FDY-8801 for cachexia, and running Iocyte AMI-3 Phase 3 in anterior STEMI PCI; Iocyte AMI Phase 2 completed showing cardiac and inflammatory biomarker reductions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Faraday Pharma company profile →
Merus Labs
HQ: Canada
Website
- Description: Provider of pharmaceutical products across broad therapeutic classes, leveraging an opportunistic product acquisition strategy to source acquisition candidates and access targets not available to other players.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Merus Labs company profile →
Kaneq Bioscience
HQ: Canada
Website
- Description: Provider of pharmaceutical discovery and early-stage development, operating in Montreal as a spinout of Kaneq Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kaneq Bioscience company profile →
Inspirna
HQ: United States
Website
- Description: Provider of oncology therapeutics and discovery technology, including ompenaclid (RGX-202), an oral SLC6A8 inhibitor in Phase 2 for advanced RAS-mutant colorectal cancer; abequolixron (RGX-104), an oral LXR/APOE activator in Phase 1b/2 for advanced non-small cell lung and endometrial cancer; the RNA-DRIVEr platform for novel cancer drivers; and RGX-019, a preclinical MERTK-targeting ADC; with active clinical trial recruitment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inspirna company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Imbria
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Imbria
2.2 - Growth funds investing in similar companies to Imbria
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Imbria
4.2 - Public trading comparable groups for Imbria
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →